Effective transduction by self-complementary adeno-associated viruses of human dendritic cells with no alteration of their natural characteristics

Journal of Gene Medicine

Volumn 10, Issue 7, 2008, Pages 762-769

  Shin, Ohkyu ^a   Kim, Sung Jin ^a   Lee, Won Il ^a   Kim, Jee Yeon ^a   Lee, Heuiran ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Dendritic cell; Maturation; Recombinant adeno associated virus; Serotype; Transduction efficiency

Indexed keywords

ANTIGEN; CELL SURFACE MARKER; INTERLEUKIN 12; INTERLEUKIN 4; PARVOVIRUS VECTOR;

ANTIGEN FUNCTION; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL ISOLATION; CELL MATURATION; CELL POPULATION; CELL VIABILITY; CYTOTOXICITY; DENDRITIC CELL; FLOW CYTOMETRY; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS RECOMBINANT;

ADENO-ASSOCIATED VIRUS;

EID: 48949120130     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1204     Document Type: Article

References (38)

1. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001; 106: 255-258.
2. Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001; 106: 259-262.
3. Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180: 83-93.
4. Ratzinger G, Stoitzner P, Ebner S, et al. Matrix metalloproteinases 9 and 2 are necessary for the migration of Langerhans cells and dermal dendritic cells from human and murine skin. J Immunol 2002; 168: 4361-4371.
5. Figdor CG, de Vries IJ, Lesterhuis WJ, et al. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10: 475-480.
6. Banchereau J, Schuler-Thurner B, Palucka AK, et al. Dendritic cells as vectors for therapy. Cell 2001; 106: 271-274.
7. Jenne L, Schuler G, Steinkasserer A. Viral vectors for dendritic cell-based immunotherapy. Trends Immunol 2001; 22: 102-107.
8. Tan PH, Beutelspacher SC, Xue SA, et al. Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood 2005; 105: 3824-3832.
9. Flotte TR. Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Ther 2004; 11: 805-810.
10. Goncalves MA. Adeno-associated virus: from defective virus to effective vector. Virol J 2005; 2: 43.
11. Liu Y, Santin AD, Mane M, et al. Transduction and utility of the granulocyte-macrophage colony-stimulating factor gene into monocytes and dendritic cells by adeno-associated virus. J Interferon Cytokine Res 2000; 20: 21-30.
12. Ponnazhagan S, Mahendra G, Curiel DT, et al. Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy. J Virol 2001; 75: 9493-9501.
13. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 2001; 8: 1248-1254.
14. Rabinowitz JE, Rolling F, Li C, et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002; 76: 791-801.
15. Su H, Huang Y, Takagawa J, et al. AAV serotype-1 mediates early onset of gene expression in mouse hearts and results in better therapeutic effect. Gene Ther 2006; 13: 1495-1502.
16. Blankinship MJ, Gregorevic P, Allen JM, et al. Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol Ther 2004; 10: 671-678.
17. Wang Z, Zhu T, Qiao C, et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 2005; 23: 321-328.
18. Kim SJ, Lee WI, Heo H, et al. Stable gene expression by self-complementary adeno-associated viruses in human MSCs. Biochem Biophys Res Commun 2007; 360: 573-579.
19. Aldrich WA, Ren C, White AF, et al. Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands. Gene Ther 2006; 13: 29-39.
20. Nam YR, Kim SJ, Lee B, et al. Analysis of the production efficiency and titration of various recombinant adeno-associated viruses. Oncol Rep 2004; 12: 761-766.
21. Moon MS, Joo CH, Hwang IS, et al. Distribution of viral RNA in mouse tissues during acute phase of coxsackievirus B5 infection. Intervirology 2005; 48: 153-160.
22. Zhou LJ, Tedder TF. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA 1996; 93: 2588-2592.
23. Smyth CM, Logan G, Boadle R, et al. Differential subcellular localization of CD86 in human PBMC-derived macrophages and DCs, and ultrastructural characterization by immuno-electron microscopy. Int Immunol 2005; 17: 123-132.
24. Inaba K, Steinman RM, Pack MW, et al. Identification of proliferating dendritic cell precursors in mouse blood. J Exp Med 1992; 175: 1157-1167.
25. Xin KQ, Mizukami H, Urabe M, et al. Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells. J Virol 2006; 80: 11899-11910.
26. McCarty DM, Fu H, Monahan PE, et al. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 2003; 10: 2112-2118.
27. Wang Z, Ma HI, Li J, et al. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 2003; 10: 2105-2111.
28. Lee HS, Shin OK, Kim SJ, et al. Efficient gene expression by self-complementary adeno-associated virus serotype 2 and 5 in various human cancer cells. Oncol Rep 2007; 18: 611-616.
29. Grieger JC, Samulski RJ. Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J Virol 2005; 79: 9933-9944.
30. Wu J, Zhao W, Zhong L, et al. Self-complementary recombinant adeno-associated viral vectors: packaging capacity and the role of rep proteins in vector purity. Hum Gene Ther 2007; 18: 171-182.
31. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72: 1438-1445.
32. Chen S, Kapturczak M, Loiler SA, et al. Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors. Hum Gene Ther 2005; 16: 235-247.
33. Seiler MP, Miller AD, Zabner J, et al. Adeno-associated virus types 5 and 6 use distinct receptors for cell entry. Hum Gene Ther 2006; 17: 10-19.
34. Halbert CL, Allen JM, Miller AD. Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J Virol 2001; 75: 6615-6624.
35. Tahara I, Miyake K, Hanawa H, et al. Systemic cancer gene therapy using adeno-associated virus type 1 vector expressing MDA-7/IL24. Mol Ther 2007; 15: 1805-1811.
36. Passini MA, Bu J, Fidler JA, et al. Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann-Pick mouse. Proc Natl Acad Sci USA 2007; 104: 9505-9510.
37. Hirschowitz EA, Weaver JD, Hidalgo GE, et al. Murine dendritic cells infected with adenovirus vectors show signs of activation. Gene Ther 2000; 7: 1112-1120.
38. Perreau M, Mennechet F, Serratrice N, et al. Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy. J Virol 2007; 81: 3272-3284.